PVLA: חוב לטווח קצר של החברה Pieris Pharmaceuticals

The price history of Pieris Pharmaceuticals (PVLA) reflects the situation of a company lacking its own revenue and relying on external financing, with the indicator standing at 0.00. The business focuses on creating synthetic anticalins for inhalation lung therapy. The issuer's future depends on a revision of its development strategy and the search for major partners to cover research costs and replenish reserves.

Pieris Pharmaceuticals (PVLA) is implementing closed-loop water systems and reducing toxic emissions as part of its ESG strategy. The modernization of biotechnological facilities requires precise liquidity control to service current obligations. This metric aggregates the total amount of all loans and borrowings with a maturity of up to one year. It measures short-term financial stability and default risk. By analyzing fluctuations in short-term debt, an investor assesses the company's efficiency in managing working capital.